Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) shares gapped down before the market opened on Monday after the company announced weaker than expected quarterly earnings. The stock had ...

Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to $15.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what ...

Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, ...

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.19 per share a year ago.

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company delivered weak fourth-quarter 2024 results, with sales, operating profits ...